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Abstract
Background: Current treatment options for Palmoplantar Pustulosis (PPP), a debilitating chronic skin disease which
affects the hands and feet, are limited. The Anakinra for Pustular psoriasis: Response in a Controlled Trial (APRICOT)
aims to determine the efficacy of anakinra in the treatment of PPP. This article describes the statistical analysis plan
for the final analysis of this two-staged trial, which was determined prior to unblinding and database lock. This is an
update to the published protocol and stage one analysis plan.
Methods: APRICOT is a randomised, double-blind, placebo-controlled trial of anakinra versus placebo, with two
stages and an adaptive element. Stage one compared treatment arms to ensure proof-of-concept and determined
the primary outcome for stage two of the trial. The primary outcome was selected to be the change in
Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at 8 weeks. Secondary outcomes include other
investigator-assessed efficacy measures of disease severity, participant-reported measures of efficacy and safety
measures. This manuscript describes in detail the outcomes, sample size, general analysis principles, the pre-
specified statistical analysis plan for each of the outcomes, the handling of missing outcome data and the planned
sensitivity and supplementary analyses for the second stage of the APRICOT trial.
Discussion: This statistical analysis plan was developed in compliance with international trial guidelines and is
published to increase transparency of the trial analysis. The results of the trial analysis will indicate whether anakinra
has a role in the treatment of PPP.
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Registered on 1 April 2016.
Keywords: Psoriasis, Palmoplantar pustulosis, Randomised controlled trial, Anakinra, Adaptive trial,, Statistical
analysis plan
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: s.cro@imperial.ac.uk
1Imperial Clinical Trials Unit, Imperial College London, W12 7RH, London, UK
Full list of author information is available at the end of the article
Cro et al. Trials          (2020) 21:158 
https://doi.org/10.1186/s13063-020-4103-z
Background
Palmoplantar pustulosis (PPP) is a debilitating chronic
skin disease which affects the hands and feet. PPP
produces intensely inflamed skin, covered with pus-
tules. Unfortunately treatment options are currently
limited [1]. Recent evidence suggests that interleukin-
1 (IL-1), a cytokine known to sustain the inflamma-
tory responses initiated by skin keratinocytes, may
have a role in PPP [2–4]. Therefore, IL-1 blockade is
hypothesized to be effective in the treatment of PPP.
Anakinra for Pustular Psoriasis: Response in a
Controlled Trial (APRICOT) is a randomised, double-
blind, placebo-controlled trial with two stages and an
adaptive element which aims to determine the efficacy
of anakinra in the treatment of adults with palmoplantar
pustulosis (PPP). Full details on the rationale and back-
ground to the trial can be found in the published study
protocol [5].
Since PPP is a rare condition and prior existing
proof-of-concept data for anakinra are limited, APRI-
COT was designed to include two stages. Prior to the
completion of a fully powered efficacy assessment
(stage two), we compared the treatment arms at the
end of stage one to provide reassurance for safety
and evidence for potential treatment benefit. Stage
one was also designed to confirm the primary out-
come measure for the fully powered treatment com-
parison in stage two. The statistical analysis plan,
which details the analyses undertaken in stage one,
has previously been published [6]. The current docu-
ment describes the statistical analyses to be under-
taken at the end of stage two (the final analysis of
the double-blind randomised controlled trial). The
plan was approved by Catherine Smith (Chief investi-
gator), Victoria Cornelius (Senior statistician), Suzie
Cro (Trial Statistician) and Edel O’Toole (Trial Steer-
ing Committee chair) prior to database lock and to
the unblinding of the trial statistician following data-
base lock.
Trial status
Recruitment to APRICOT began in October 2016. Stage
one recruitment completed in September 2017 when a
total of 24 patients had been randomised. Interim ana-
lysis at the end of Stage one, involving n = 24 patients,
compared treatment arms to ensure sufficient efficacy
following the pre-specified APRICOT stage one statis-
tical analysis plan (SAP) [6]. The trial passed the stop/go
efficacy criteria to progress to stage two, and a decision
to embark on stage two, which involved a further 40
participants and was powered to determine efficacy, was
made by the independent data monitoring committee
(IDMC).
At the end of stage one, the IDMC assessed the distri-
butions and reliability of two candidate outcomes to es-
tablish which one should be confirmed as the primary
outcome. Following an assessment of reliability (as pre-
specified in the stage one SAP [6]), the primary outcome
for stage two was chosen to be the change in disease ac-
tivity over 8 weeks, adjusted for baseline, measured using
Palmoplantar Pustulosis Psoriasis Area and Severity
Index (PPPASI).
In July 2019 an optional open label extension was
added to the trial and offered to all patients who
complete the 8-week treatment period and the 12-
week follow up visit, including those who had com-
pleted the treatment period in previous years. Follow-
ing slower than projected recruitment rates, all
aspects of the trial design were critically reviewed,
and an open label extension was one modifiable elem-
ent. The primary purpose of the open label extension
was to enhance the slow recruitment to the rando-
mised, double-blind, placebo-controlled study, so that
all participants have the potential opportunity to ac-
cess anakinra. This change was informed by feedback
from recruiting clinicians and patient reasons
recorded for declining to take part in the trial. Re-
cruitment to stage two is due to complete by the end
of January 2020. Data collection for the double-blind
randomised controlled trial is expected to complete
by April 2020, and statistical analysis will be per-
formed following data cleaning checks and database
lock.
Objectives
The primary objective of APRICOT is to determine the
efficacy of anakinra on the change in disease activity
over 8 weeks, measured using the PPPASI, in the treat-
ment of adults with PPP compared to placebo.
Secondary objectives
The secondary objectives of the trial include the
following:
 Estimate the efficacy of anakinra on the change in
disease activity over 8 weeks, measured using pustule
count compared to placebo
 Compare the time to response of PPP and the
relapse rate with anakinra to placebo
 Estimate the proportion of patients who achieve
clearance of PPP with anakinra compared to placebo
by 8 weeks
 Estimate the treatment effect of anakinra in pustular
psoriasis at non-acral sites
 Estimate the treatment effect of anakinra in plaque-
type psoriasis
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 Collate data on the adverse event profile and
adverse reactions induced by anakinra and
compare to placebo to evaluate the safety and
tolerability of anakinra in the treatment of PPP
 Determine the effect of anakinra on patients quality
of life compared to placebo
 Assess whether patients find treatment with
anakinra acceptable or worthwhile
 Estimate adherence to treatment with anakinra
Methods/Design
Trial design
Anakinra for Pustular psoriasis: Response in a
Controlled Trial (APRICOT) is a randomised, double-
blind, placebo-controlled trial with two stages and an
adaptive element, followed by an open label exten-
sion. Participants will be allocated to 8 weeks of treat-
ment with either anakinra or placebo and will return
for a visit 4 weeks after treatment is completed (12
weeks). All participants who complete the 8-week
treatment period and the 12-week follow-up visit will
be offered the open label extension on anakinra for 8
weeks. The protocol for the APRICOT trial has been
published previously and gives full details on the
intervention under study and the inclusion and exclu-
sion criteria [5].
Randomisation and blinding
Eligible participants with PPP will be randomised (1:
1) to receive treatment with anakinra or placebo via
subcutaneous daily injections for 8 weeks. To ensure
allocation concealment, participants will be rando-
mised using an online randomisation system by the
King’s Clinical Trial Unit. Participants will be allo-
cated to treatment arms using blocked randomisation
stratified by centre.
Throughout the trial participants, research nurses,
treating physicians and independent outcome assessors
will be blinded to treatment assignment. The trial statis-
tician will also be subgroup blind throughout the rando-
mised trial. That is, the trial statistician will observe the
data as group A versus group B, without knowing which
treatments A and B refer to. The senior statistician who
conducted the stage one analysis was subgroup-blind
throughout stage one and was unblinded at the end of
stage one.
Outcomes
Primary outcome
The primary outcome is the disease activity at 8
weeks measured using the Palmoplantar Pustulosis
Psoriasis Area and Severity Index (PPPASI), adjusted
for baseline PPPASI.
Secondary outcomes
Secondary outcomes for APRICOT include the
following:
Investigator assessed efficacy measures, which include
 Fresh pustule count on palms and soles at 8
weeks (measured at week 1, 4 and 8), adjusted for
baseline
 Total pustule count on palms and soles at 8 weeks
(measured at week 1, 4 and 8), adjusted for baseline
 PPP - Investigator’s Global assessment (PPP-IGA) at
8 weeks (measured at week 1, 4 and 8), adjusted for
baseline
 Time from randomisation to response of PPP (where
response is defined as a 75% reduction in fresh
pustule count compared to baseline)
 Time from randomisation to relapse (where
relapse is defined as return to baseline fresh
pustule count)
 Achievement of ‘clear’ on PPP-IGA, at 8 weeks
 Development of a disease flare (i.e., > 50%
deterioration in PPPASI compared to baseline) at 8
weeks
 Pustular psoriasis at non-acral sites (not hands and
feet), as measured by percentage area of involvement
at 8 weeks (measured at week 1, 4 and 8), adjusted
for baseline
 Plaque type psoriasis (if present) measured using
Psoriasis Area and Severity Index (PASI) at 8
weeks (measured at week 4 and 8), adjusted for
baseline.
Participant reported efficacy outcomes, which include
 Participant’s Global Assessment (PGA, as clear,
nearly clear, mild, moderate, severe, very severe)
over 8 weeks adjusted for baseline (measured at 1, 4,
and 8 weeks)
 Palmoplantar Quality of Life Instrument score at 8
weeks, adjusted for baseline
 Dermatology Life Quality Index (DLQI) at 8 weeks
adjusted for baseline
 EQ5D-3 L at 8 weeks adjusted for baseline
 Treatment acceptability (i.e., whether the
treatment is ‘worthwhile’) evaluated using a
brief questionnaire with a response scale of
1–5 at week 12 (after the last treatment dose
at the end of the study, prior to the final safety
visit)
 Adherence to treatment measured by self-recall and
responses to daily text messages over 8 weeks of
treatment.
Safety measures, which include
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 Serious infection as defined by any infection leading
to death, hospital admission or requiring IV
antibiotics
 Neutropenia (i.e., neutrophil count of ≤ 1.0 × 109/l
on at least one occasion)
 Serious adverse events (SAE), Serious adverse
reactions (SAR), or Unexpected serious adverse
reactions (USAR), which include any adverse
event, adverse reaction or unexpected adverse
reaction, respectively, that results in death, is life-
threatening, required hospitalisation or prolonga-
tion of existing hospitalisation, results in persist-
ent or significant disability or incapacity, or
consists of a congenital anomaly or birth defect
 Adverse events (AE) and Adverse reactions (AR)
including unexpected adverse reactions (UAR).
Additional exploratory/mechanistic outcomes will be
collected during APRICOT. These outcomes will not
contribute to the trial’s main findings and primary re-
sults publication, so they do not form part of the
main trial statistical analysis plan and will be de-
scribed in more detail in a separate analysis plan.
Sample size
The sample size for APRICOT was undertaken at the
design stage and prior to the completion of stage one,
when the primary outcome of the main trial analysis
was unknown. Consequently, the sample size was cal-
culated using a standardised effect size. Given the
high patient burden due to the requirement for daily
self-administered subcutaneous injections and costs of
the drug, an effect size of 0.9 Standard Deviations
(SDs) was chosen to be the minimum important dif-
ference to detect with good power. Larger effect sizes
have been reported when oral retinoids are used as
the recommended systemic intervention for pustular
psoriasis [1, 7]. With 90% power and a 5% signifi-
cance level, for the detection of a difference of 0.9
SD, a sample size of 27 per arm is required. To allow
for a conservative approximate 15% withdrawal rate,
32 participants per arm (N = 64 in total) are required.
After recruitment had been extended by an extra
12 months, by November 2019, 57 patients had been
randomised into the APRICOT trial. The APRICOT
Trial Management Group (TMG) met to discuss the
lower than anticipated recruitment and the studies
statistical power was considered for various sample
size numbers as a contingency in the event of lower
than planned recruitment. To detect a difference of
0.9 SD, with 80% power and a 5% significance level,
while allowing for a conservative approximate 15%
withdrawal rate, a sample size of 25 per arm (N = 50
in total) is required. Consequently, the decision was
made to allow the trial to continue to recruit as many
patients as possible within the funding constraints,
given at least 80% power will be achieved.
Statistical analysis plan
General analysis principles
The final (stage two) analysis will be performed after
all recruited participants have completed 20 weeks of
follow-up post-treatment initiation. Analyses will be
carried out by the sub-group-blinded trial statistician
and will follow the intention-to-treat (ITT) principle.
That is, all eligible randomised participants with base-
line and at least one recorded outcome (over 8 weeks)
will be analysed in the treatment arms to which the
participant was allocated, regardless of the treatment
subsequently received. The safety set (SS) population
consists of all participants who received at least one
dose of the assigned intervention and will be used in
the analysis to describe adverse events.
All regression analyses will include adjustment for
centre where appropriate, as this was a stratification
factor in the randomisation; therefore, inclusion of
this adjustment is necessary in the analysis to main-
tain the correct type I error rate [8, 9]. Additionally,
for continuous outcomes, the outcome measured at
baseline will be included in regression analyses to in-
crease the power [10]. All confidence intervals will be
two-sided and at the 95% level. A p-value < 0.05 will
be interpreted as statistically significant for the pri-
mary outcome.
Recruitment and participant flow
The number of participants randomised will be sum-
marised by treatment arm and study centre (Appendix
in Table 3). To summarise the patient flow through the
trial, a Consolidated Standards of Reporting Trials
(CONSORT) flow chart will be constructed [11] see
(Fig. 1). This will include the number of patients
screened, eligible and randomised into the trial, with-
drawing from treatment and lost to follow-up, and the
number included in the analyses.
Baseline comparability of randomised groups
Baseline characteristics will be summarised by rando-
mised treatment arm. The variables to be summarised
are presented in Appendix in Table 4. Categorical
variables will be summarised by number and percent-
age in each category. Continuous variables will be
summarised by mean and standard deviation for ap-
proximately normally distributed variables or median
and interquartile range for non-normally distributed
variables. No formal statistical tests will be performed
because any differences between treatment arms at
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baseline will be the result of chance rather than bias
due to randomisation.
Withdrawals, loss to follow-up and missing data
The number withdrawing from the trial, including those
lost to follow-up, will be reported by treatment arm and
time point along with the reasons for the withdrawal.
The overall loss to follow-up will be tabulated by treat-
ment arm and visit. The proportions of participants
missing PPPASI values (primary outcome) will be sum-
marised in each arm and at each time point for which
measurement is planned (see Appendix in Tables 5, 6, 7
and 8).
Adherence to allocated treatment
The number discontinuing the trial drug will be re-
ported by treatment arm and week along with the
reasons for the discontinuations (Appendix in Tables
9 and 10). Self-reported treatment adherence, as mea-
sured by responses to daily text messages and self-
reported by patients using a paper trial diary or ver-
bally self-recalled at study visits, will be reported by
treatment arm and week for patients who have not
yet discontinued the treatment or withdrawn from the
study by the given week (Appendix in Table 11). An
injection will be classed as being received if either a
SMS response of ‘Yes’ is recorded for the day in
question or if self-reported as a ‘Yes’. The adherence
to the planned visit windows will also be summarised
by treatment arm and visit (Appendix in Table 12).
Rescue therapy, topical therapy and prohibited medication
The proportion of participants using investigator-
directed ‘rescue’ medication, as summarised in Table 1,
in the form of potent corticosteroid (e.g., mometasone
furoate, betamethasone valerate ointment or cream) and
the duration of use and amount used will be summarised
by treatment arm (Appendix in Tables 13, 14 and 15).
We will plot histograms for the number of days of use of
rescue therapy by treatment arm, plot the proportion of
participants on rescue therapy over time and the cumu-
lative proportion of participants initiated on rescue ther-
apy over time.
Fig. 1 Template CONSORT diagram for APRICOT
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Where data allows, we will also summarise the overall
proportion of participants using topical therapy during
the treatment period, the duration of use and the
amount used; histograms for the number of days of use
of topical therapy will be constructed by treatment arm,
and we will plot the proportion of participants on topical
therapy over time.
If any prohibited medications are used (as defined in
Table 1), we will also summarise the proportion of par-
ticipants using prohibited medication, the prohibited
medication used, the duration of use and the amount
used.
Descriptive statistics for outcome measures
Descriptive statistics will be presented for all outcome
measures by treatment arm. For each primary and
secondary outcome that is recorded at multiple time
points, the outcome will be summarised by visit and
treatment arm (Appendix in Tables 16, 17, 18, 19, 20,
21, 22 and 23). Summary statistics with 95%
confidence intervals will also be plotted in line graphs
for each outcome across time by intervention. Only
participants with a completely recorded outcome will
be used to calculate the summary measures.
Adverse event reporting
Information on adverse events will be collected by
means of spontaneous reports from participants and
carers, clinical observation and clinical examinations
and blood tests. A safety set (SS) population will be
used for describing adverse events. This SS population
will include all participants who receive at least one
injection of study drug or placebo. For each event,
local clinical investigators rate the relationship to the
study medication as none/unlikely/possible/likely/def-
inite. Adverse Reactions (AR) consist of the subset of
non-serious adverse events (AE) rated to have a pos-
sible/likely/definite relationship with the study medi-
cation. Serious Adverse Reactions (SAR) consist of
the subset of serious adverse events (SAE) rated to
have a possible/likely/definite relationship with the
study medication. If the event is considered related to
the study medication, then local clinical investigators
will also rate whether the reaction was unexpected
(Yes/No). Events will be coded using terms of the
clinical investigators choosing with reference to Med-
ical Dictionary for Regulatory Activities (MedDRA) at
the ‘Preferred Terms’ level.
Adverse events will be summarised by type (AE,
AR, unexpected adverse reactions (UAR, a subset of
the ARs), serious adverse events (SAE), serious ad-
verse reactions (SAR, a subset of the SAEs) and unex-
pected serious adverse reactions (USAR, a subset of
the SARs)), and by treatment arm. Adverse events will
be tabulated by treatment group for both the number
of events and the number of participants with the
type of event.
A listing will be produced detailing all Serious Ad-
verse Events (SAEs) and Reactions (SARs). Non-
serious adverse events and reactions will be listed by
MedDRA preferred term level. Non-serious adverse
events will also be summarised by MedDRA system
organ class and intensity (subjectively assessed by
local clinical investigators as mild/moderate/severe).
The number of events related to an infection will be
tabulated. Details will be provided for those events re-
lated to infection, including the treatment prescribed,
where applicable.
No hypothesis testing will be undertaken for adverse
event outcomes, but approaches to assess signals for
ARs will be explored, as described below (Appendix in
Tables 24, 25, 26, 27, 28, 29, 30, 31 and 32). An adverse
event of particular interest is injection site reaction. We
will also separately analyse serious infections, defined by
any infection leading to death, prolonged hospital admis-
sion or requiring IV antibiotics, as described below in
further detail.
Analysis of primary outcome
The mean difference in the week 8 PPPASI, adjusted
for baseline, between the two treatment groups will
be estimated using a mixed-effects linear (Gaussian)
regression model. The model will include a random
intercept for participants with fixed effects for time,
treatment group, time-by-treatment group interaction
Table 1 Summary of concomitant therapy rules
Prohibited Very potent topical corticosteroids (e.g., Dermovate)
Any topical treatment that is likely to impact signs
and symptoms of PPP (e.g., corticosteroids, vitamin D
analogues, calcineurin inhibitors, retinoids, keratolytics,
tar or urea)
Phototherapy or PUVA
Methotrexate, Cyclosporine, Acitretin, Alitretinoin, FAE
Etanercept or Adalimumab
Infliximab or Ustekinumab or Secukinumab
Other TNF antagonists
Other systemic immunosuppressive therapy
Other investigational monoclonal antibody
Other investigational drugs
Allowable topical
therapy
Emollients
Topical hydrocortisone, antihistamine for injection –
site reactions
Mild topical corticosteroids for the treatment of
psoriasis at sites other than hands and feet applied
with gloves
‘Rescue’ topical
therapy
Potent corticosteroid OD. To be dispensed only by
the study team, at the Investigator’s discretion.
Amounts prescribed to be recorded.
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and baseline PPPASI. Centre will be included in the
model either as a random or fixed effect depending
on the total number of centres recruiting to the study
and the average number of participants recruited
from each centre. The estimated treatment effect at 8
weeks will be reported with a 95% confidence interval
and corresponding p-value. As the model adjusts for
baseline PPPASI, this is equivalent to analysing the
change from baseline with adjustment for baseline
[12]. The main conclusion of the trial will be based
on this analysis time point. We will also report the
treatment effect at weeks 1 and 4.
Approximately 15 centres are anticipated to recruit,
and therefore, a relatively small number of partici-
pants will be recruited per centre. Since random
centre effects have been shown to be superior to
fixed effects in terms of power and precision when
the number of participants per centre is small, and
equivalent to fixed effects when the number of partic-
ipants per centre is larger [9, 13], the default option
will be to include centre as a random effect. With
centre as a random effect, where Yijk denotes the
PPPASI measurement for participant i at time j from
centre k, the primary analysis model will be model A:
Y ijk ¼ β0 þ β1TRTi þ β2PPPASI0i þ β3t4 þ β4t8
þ β5t4TRTi þ β6t8TRTi þ b1;i þ b2;k þ eijk
where j = 1 to 3 time points (week 1, 4, and 8), i = 1 to
64 participants, and k = 1 to ~ 15 centres; TRTi is the
dummy variable (TRTi = 0 or 1) for participant i;
PPPASI0i is the baseline PPPASI for participant i; tx is
the dummy variable for time (= 0 or 1) at time point x
weeks; Week 1 is represented by t4 = 0 and t8 = 0; and
b1;i  Nð0; σ2b1Þ, b2;k  Nð0; σ2b2Þ, and eijk  Nð0; σ2eÞ,
Within model A,b1, i and b2, k are random intercepts
at the participant level and centre level, respectively.
Each of b1, i, b2, k and eijk are assumed to follow normal
distributions. An unstructured covariance matrix will be
used [14]. The treatment effect at 8 weeks, β1 + β6,will be
of primary interest. If, however, the variation between
centres is low and the model fails to converge, then
centre will be treated as a fixed effect instead. With
centre as fixed, where yijk denotes the PPPASI measure-
ment for participant i at time j from centre k, the pri-
mary analysis model will be model B:
Y ijk ¼ β0 þ β1TRTi þ β2PPPASI0i þ β3t4 þ β4t8
þ β5t4TRTi þ β6t8TRTi þ β7kCENTREi
þ b1;i þ eijk
where j = 1 to 3 time points (week 1, 4, and 8) and i = 1
to 64 participants; TRTiis the dummy variable (TRTi = 0
or 1) for participant i; PPPASI0i is the baseline PPPASI
for participant i;
tx is the dummy variable for time (= 0 or 1) at time
point x weeks; Week 1 is represented by t4 = 0 and t8 =
0; β7k is a dummy variable for each centre k; for centre
1, β7k will be constrained to be 0; and b1;i  Nð0; σ2b1Þ
and eijk  Nð0; σ2eÞ,
Within model B, b1, i is a random intercept at the par-
ticipant level. Both eijk and b1, i follow normal distribu-
tions. An unstructured covariance matrix will be used.
The treatment effect at 8 weeks, β1 + β6,will be the mean
treatment effect of primary interest.
Models will be fitted using restricted maximum likeli-
hood (REML). Both models make assumptions about
random effects distributions, correlation structure and
residuals, which will all be investigated. If including
centre as a fixed effect results in unstable model esti-
mates, e.g., if a number of sites (> 1) have very few ran-
domisations (≤3), we will exclude centre from the model
(model C). Stata code for the primary outcome analysis
is displayed in Table 2.
Sensitivity analysis of primary outcome
Every effort will be made to obtain follow-up data for
all participants including those who stop treatment.
The primary analysis will include all observed data
and employ maximum likelihood estimation.This ap-
proach is efficient for handling missing outcome data
under the missing-at-random assumption (MAR).
That is, the probability of missing data is assumed to
not be dependent on the values of the unobserved
data themselves, but instead conditional on the ob-
served values of the variables included in the analysis
model.
Sensitivity analyses addressing the impact of missing
data will explore departures from the main MAR ana-
lysis assumption and potential missing not at random
(MNAR) mechanisms using Multiple Imputation (MI)
and a pattern mixture approach (Carpenter and Ken-
ward, 2008) for all patients on the primary outcome
following the ITT principle. Imputation under MAR
will initially be performed separately within each
treatment arm using chained equations following the
guidance suggested by White et al. [15]. The variables
in the imputation model will be the same as those in
the analysis model without including more auxiliary
variables after taking into account the relatively small
sample size of this study [16]. Imputations will then
be modified to investigate the impact of a better or
poorer response than that predicted by MAR (lower/
higher PPPASI scores) for participants with missing
data. To do this, we will define δ as the postulated
mean difference in the rate of change of the PPPASI
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score between the observed and unobserved cases for
each week unobserved. For each participant in each
intervention arm, we will then modify the MAR im-
puted observations accordingly by δ. Imputed data
sets will be analysed using the primary analysis
model. Results will be combined across imputed data
sets using Rubin’s rules. We will repeat the analysis
for a range of δ corresponding to +/− 10, 20, 30, 40
and 50% of the rate of change of the PPPASI over 8
weeks in all observed participants. We will also con-
sider the possibility that data is missing informatively
in one arm only. Only imputations for active arm
participants will be modified for a range of δ corre-
sponding to +/− 10, 20, 30, 40 and 50% of the rate of
change of the PPPASI observed over 8 weeks in the
active arm and the primary analysis repeated. Subse-
quently, only imputations for placebo participants will
be modified as described above. Fifty imputations will
be run for each MI analysis.
Supplementary analysis for the primary outcome
Four supplementary analyses are pre-planned for the tri-
als primary outcome:
1. Supplementary analysis accounting for use of
rescue therapy—Data after the initiation of
rescue therapy will be set as missing. The
primary analysis model will be fitted to data
prior to the use of rescue therapy along with all
observed data for patients who do not initiate
rescue therapy to estimate the treatment effect in
the absence of rescue therapy because
participants who were initiated on rescue therapy
are assumed to have had a similar outcome to
those observed with the same history and profile
in the absence of rescue therapy (MAR). Since
the rescued participants would typically have had
worse outcomes than those observed in the
absence of rescue therapy, a pattern-mixture MI
approach will subsequently be used to explore
the impact of worse outcomes among the
participants initiated on rescue therapy. Imput-
ation under MAR will initially be performed as
described above. We will define δR as the postu-
lated mean difference in the rate of change of
the PPPASI between the observed and rescued
cases for each week post-rescue. For each partici-
pant initiating rescue therapy, we will then mod-
ify their MAR imputed observations accordingly
by δR. Imputed datasets will be analysed using
the primary analysis model. Results will be com-
bined across imputed datasets using Rubin’s rules.
We will repeat the analysis for a range of δR cor-
responding to 10%, 20%, 30%, 40% and 50% of
the change in the PPPASI observed in those with
complete data over 8 weeks. For each MI ana-
lysis, 50 imputations will be run. These delta-
adjusted sensitivity analyses will each provide an
estimate of the treatment effect in the absence of
rescue therapy, where participants who were ini-
tiated on rescue therapy are assumed to have
had a specific poorer outcome than those ob-
served with the same history and profile in the
absence of rescue therapy.
2. Supplementary analysis accounting for use of
prohibited medication—Data post initiation of
rescue therapy and prohibited medication will be
set as missing, and the analytical approach
outlined above for accounting for rescue therapy
will be adopted, but applied to individuals with
data missing after rescue therapy or after
prohibited medication use.
3. Supplementary analysis accounting for use of
topical therapy—Where data allow, data will be
set as missing when participants are on topical
therapy at the time of the study follow-up visit.
The primary analysis model will be fitted to data
for participants not on topical therapy, along
with all observed data for patients who do not
initiate topical therapy. This analysis will provide
an estimate of the treatment effect in the absence
of topical therapy, under the assumption that
Table 2 Statistical analysis code for the primary outcome
Model Analysis method Stata code for analysis
A Primary analysis: The PPPASI will be analysed using a linear mixed effects model, with
fixed effects for time, treatment group, time-by-treatment group interaction and
baseline PPPASI. The model will include a random intercept for participants and centre
of recruitment.
mixed pppasi treat##i.time base_pppasi ///
|| centre: || id:, covariance(unstructured) reml
B If Model A fails to converge: Model A without the random-effect for centre, centre will
instead be included as a fixed effect
mixed pppasi treat##i.time base_pppasi i.centre ///
|| id:, covariance(unstructured) reml
C If Model A fails to converge and > 1 site has ≤3 randomised: Primary analysis model
excluding centre as a random or fixed effect
mixed pppasi treat##i.time base_pppasi ///
|| id:, covariance(unstructured) reml
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participants who were initiated on topical therapy
would have had a similar outcome to those ob-
served with the same history and profile in the
absence of topical therapy (MAR). Subsequently,
data after the initiation of rescue therapy and
prohibited medication will be set as missing, as
well as data for participants while on topical
therapy, and the analytical approach outlined
above for accounting for rescue therapy will be
adopted, but applied to individuals who are miss-
ing data from their time on topical treatment or
after rescue therapy or prohibited medication
use.
4. Supplementary analysis to estimate the complier
average causal effect—For each participant, the
proportion of injections received relative to
injections planned (8 × 7 = 56) will be calculated
and summarised based on the recorded daily
adherence data. The complier average causal
effect (CACE) will be estimated by a two-stage
least squares instrumental variable regression for
the primary endpoint (using ivregress 2sls in
Stata). Here, we will initially define a ‘complier’
as an individual who complete more than 50% of
the injections, that is, injections received relative
to injections planned for the 8-week study
period. Randomisation will be used as an instru-
mental variable for treatment received with ad-
justment for centre and baseline PPPASI on the
week 8 outcome. Subsequently, we will alterna-
tively define a ‘complier’ as an individual who
completes ≥ 60%, ≥ 70%, ≥ 80% and ≥ 90% of in-
jections, and we will employ the same analysis
approach to address the impact of alternative
definitions of compliance. If including centre as a
fixed effect results in unstable model estimates,
for example, if a number of sites have very few
randomisations, we will exclude centre from the
model and adjust for baseline PPPASI only.
Analysis of secondary outcomes
Continuous secondary outcomes (fresh pustule count,
total pustule count, plaque-type psoriasis - PASI, palmo-
plantar quality of life instrument and EQ5D-3 L utility
score) will each be analysed in a similar fashion to the
primary PPPASI outcome using a linear mixed effects
model. Similar to the primary analysis model, each
model will include fixed effects for treatment group,
time, treatment group-by-time interaction and baseline
value of the associated outcome. A random patient
intercept will also be included in each of the models. If
convergence problems are experienced, the approach
outlined for the primary outcome will be followed.
Binary secondary outcomes (clear on PPP-IGA, de-
velopment of disease flare, serious infection, and neu-
tropenia) will each be analysed with a mixed logistic
regression model. The models will include a fixed ef-
fect for treatment group and centre as a random
intercept. If convergence problems are experienced,
the approach outlined for the primary outcome will
be followed. The treatment odds ratio (OR) will be
reported with 95% CI.
Ordinal secondary outcomes (PPP-IGA, PGA) will
be analysed with mixed ordinal logistic regression
models. The models will include a random intercept
for participant and fixed effects for time, treatment
group, time-by-treatment group interaction and base-
line value of the outcome. Centre will be included as
a random effect initially, but if non-convergence oc-
curs, centre will be treated as a fixed effect or will be
excluded if unstable model estimates occur. We will
report the change in odds of a one-category increase
in the outcome for patients in the active arm relative
to placebo. The ordinal logistic regression model
makes assumptions about proportional odds which
will be checked for each outcome. If the proportional
odds assumption appears to be strongly violated, a
mixed effect multinomial logit model may alterna-
tively be fitted.
For the time to event outcomes (time to response
of PPP, time and to relapse), we will initially plot
Kaplan Meier curves to visualise the unadjusted re-
sponse rate over time by treatment group. Since out-
comes are observed at relatively few discrete time
intervals (week 1, 4, 8 and 12) random-intercept com-
plementary log-log models will be used to estimate
the treatment effects for the time to event outcomes.
The model will include treatment group as a fixed ef-
fect and a random intercept for centre. The subject
specific (conditional) hazard ratio for the treatment
group will be reported with 95% CI. If convergence
problems are experienced by including centre as a
random effect, the approach outlined above will be
followed. The complementary log-log model is appro-
priate for the discrete nature of the survival data [17].
The model corresponds to proportional hazards in
continuous time. The proportional hazards assump-
tion will be checked. If this assumption is violated, an
alternative parameterisation will be used e.g., includ-
ing a treatment-by-time interaction that varies the ef-
fect by time or restrictsing the observation time.
For adverse events and reactions, a volcano plot,
constructed as described in [18], which plots the risk
difference of the non-serious adverse events and reac-
tions by the MedDRA preferred term between the
treatment arms against the p-value from a Fishers’
exact test, will be examined to identify the events
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with the strongest evidence for between arm differ-
ences. A volcano plot will also be constructed to
examine non-serious adverse events and reactions by
MedDRA system organ class. Because few SAEs are
anticipated, the SAEs will be evaluated individually,
but they may also be included in these plots if
thought to aid review. Where useful negative binomial
or zero-inflated Poisson regression models will be
used to estimate relative risks, risk differences and in-
cidence rate ratios of non-serious events by MedDRA
preferred term and/or system organ class. Where suit-
able, the timing of adverse events (using hazard plots)
by treatment arm will be examined.
Exploratory analysis
A longitudinal analysis will be undertaken using a lin-
ear (Gaussian) mixed model to determine the treatment
difference in PPPASI at 12 weeks. The analysis model
will be the same as in the primary analysis but will in-
clude additional data at 12 weeks. The treatment effect
for PPPASI at 12 weeks will be estimated and reported
with 95% CI.
Since palmar disease may respond more quickly
than plantar disease, exploratory analysis will separ-
ately estimate the efficacy of anakinra on the (i) dis-
ease activity at 8 weeks, measured using fresh pustule
count on the palms, adjusted for baseline compared
to placebo and (ii) disease activity at 8 weeks, mea-
sured using fresh pustule count on the soles, adjusted
for baseline compared to placebo. For each of the
palms and soles fresh pustule counts, a linear mixed
effects model will be used, which includes fixed ef-
fects for treatment group, time, treatment group-by-
time interaction, and baseline value of the associated
outcome. A random patient intercept will also be in-
cluded in each of the models. If convergence prob-
lems are experienced, the approach outlined for the
primary outcome will be followed.
Missing baseline data
Missing baseline data are unlikely to be problematic for
the analysis because the baseline values will be collected
at the first clinic visit and centre will naturally be
complete. However, if baseline values are missing, to
avoid a loss of power within the analyses which adjust
for baseline values, these values will be imputed with the
mean baseline value calculated from the non-missing
values using pooled data from both treatment groups.
This technique improves the statistical efficiency in the
estimation of the treatment effect and is justifiable since
randomisation ensures that baseline values are inde-
pendent of treatment group [19, 20].
Missing outcome data
The primary analysis will use all observed outcome data
and will be conducted under the MAR assumption. As
detailed above, we will conduct sensitivity analysis to as-
sess the impact of departures from the MAR assumption
on the results of the primary analysis. Secondary ana-
lyses will use all available outcome data and will also be
conducted under the MAR assumption.
Interim analysis and data monitoring
The IDMC will review safety and efficacy data at time
points of their choosing. No statistical hypothesis testing
will be completed for the IDMC. Stage one analysis did
not involve formal statistical hypothesis testing; as a re-
sult, no adjustment for interim analyses has been made.
Multiple comparisons
No multiplicity adjustments will be performed for the
analysis of secondary outcomes, and results will be
viewed as hypothesis-generating.
Discussion
We have described in detail the planned analysis for the
final stage (stage two) of APRICOT following the guide-
lines for the content of statistical analysis plans in clin-
ical trials [21]. The APRICOT trial will establish the role
of anakinra in treating PPP. This pre-specified statistical
analysis plan will increase the transparency of the data
analysis and reporting.
Trial registration
ISCRTN ISCRTN13127147 registered on 1 August 2016,
http://www.isrctn.com/ISRCTN13127147. EudraCT
Number: 2015–003600-23 registered on 1 April 2016,
https://www.clinicaltrialsregister.eu/ctr-search/search?-
query=2015-003600-23.
Appendix
Table 3 Randomisation by centre and treatment group
Group A
N (%)
Group B
N (%)
Total
N
Number randomisation to date
(dd/mm/yyyy)
Study centre
Centre 1
Centre 2
Centre 3
Centre 4
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Table 4 Baseline demographics by treatment group
Characteristic Group A
N=
Group B
N=
Total
N=
Age
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Gender
N (Nmissing)
Male, n (%)
Female, n (%)
Ethnicity
White, n (%)
Asian or Asian British, n (%)
Black or Black British, n (%)
Chinese, Japanese, Korean,
Indochinese, n (%)
Mixed race, n (%)
Other, n (%)
Smoking status
Current smoker, n (%)
Ex-smoker, n (%)
Non-smoker, n (%)
PPPASI
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Fresh pustule count (palms and soles)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Fresh pustule count (palms)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Fresh pustule count (soles)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Total pustule count (palms and soles)
N (Nmissing)
Mean (SD)
Table 4 Baseline demographics by treatment group (Continued)
Characteristic Group A
N=
Group B
N=
Total
N=
Median (IQR)
Min-Max
PPP-IGA
N (Nmissing)
Clear
Almost clear
Mild
Moderate
Severe
Participant global assessment
N (Nmissing)
Clear
Almost clear
Mild
Moderate
Severe
Very severe
DLQI
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Pustular psoriasis at non acral sites (BSA)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Generalised plaque psoriasis – PASI
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Palmoplantar quality of life instrument
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
EQ 5D- utility score
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
EQ 5D-VAS
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Table 4 Baseline demographics by treatment group (Continued)
Characteristic Group A
N=
Group B
N=
Total
N=
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Table 5 Withdrawals from trial by treatment group
Point of Withdrawal: Group A
N=
Group B
N=
Total
N=
Baseline date (n, %)
By week 1 (n, %)
By week 4 (n, %)
By week 8 (n, %)
By week 12 (n, %)
By week 20 (n, %)
Table 6 Reasons for withdrawal by treatment group
Reason Group A
N=
Group B
N=
Total
N=
Lost to follow-up (n, %)
Reason 2 (n, %)
Reason 3 (n, %)
Reason 4 (n, %)
Table 7 Loss to follow-up
Loss to follow-up Group A
N =
Group B
N =
Total
N =
Baseline
Week 1 (n, %)
Week 4 (n, %)
Week 8 (n, %)
Week 12 (n, %)
Table 8 Missing data for PPPASI
Missing Group A
N =
Group B
N =
Total
N =
Baseline
Week 1 (n, %)
Week 4 (n, %)
Week 8 (n, %)
Week 12 (n, %)
Table 9 Permanent trial drug discontinuation
Point of treatment discontinuation Group A N= Group B
N=
Total
N=
Baseline (n, %)
Week 1 (n, %)
Week 2 (n, %)
Week 3 (n, %)
Week 4 (n, %)
Week 5 (n, %)
Week 6 (n, %)
Week 7 (n, %)
Week 8 (n, %)
Table 10 Reasons for trial drug discontinuation
Reason Group A
N=
Group B
N=
Total
N=
Reason 1 (n, %)
Reason 2 (n, %)
Reason 3 (n, %)
Reason 4 (n, %)
Table 11 Self-reported adherence to treatment group
Treatment
period
Mean number of doses
per week (SMS)
Mean number of doses
per week (Diary)
Mean number of doses
per week (Total*)
N Group A
Mean
(SD)
Group B
Mean
(SD)
N Group A
Mean
(SD)
Group B
Mean
(SD)
N Group A
Mean
(SD)
Group B
Mean
(SD)
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Week 8
*SMS and Diary data combined
Table 12 Adherence to visit windows
Visit Difference |expected – actual|
Group A
N=
Group B
N=
N Mean (min, max) N Mean (min, max)
Baseline
Week 1
Week 4
Week 8
Week 12
Week 20
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Table 13 Rescue therapy by treatment group
Treatment given Group A N= Group B N= Total
N=
Treatment 1 (n, %)
Treatment 2 (n, %)
Treatment 3 (n, %)
Total
Table 14 Rescue therapy by treatment group and time point of
first initiation
Rescue initiation Group A
N=
Group B
N=
Total
N=
Prior to week 1 (n)
Prior to week 4 (n)
Prior to week 8 (n)
Prior to week 12 (n)
Prior to week 20 (n)
Total
Table 15 Days of use of rescue therapy and amount used
Rescue therapy Treatment group
A B
Number of patients taking rescue therapy
Total no. of days of use
Mean, SD
Median, IQR
Min, Max
Total amount used (g)
Mean, SD
Median, IQR
Min, Max
Average amount per use (g)
Mean, SD
Median, IQR
Min, Max
Table 16 Primary outcome, PPPASI
Time Treatment Group Total
N
Unadjusted
Mean
Difference:
(95% CI)
A B
N Mean SD N Mean SD
Baseline
Week 1
Week 4
Week 8
Week 12
Table 17 Fresh pustule count
Time Treatment Group Total
N
Unadjusted
Mean
Difference:
(95% CI)
A B
N Mean SD N Mean SD
Baseline
Week 1
Week 4
Week 8
Week 12
Table 18 Total pustule count
Time Treatment Group Total
N
Unadjusted
Mean
Difference:
(95% CI)
A B
N Mean SD N Mean SD
Baseline
Week 1
Week 4
Week 8
Week 12
Table 19 PPP-IGA
Time N
Clear Almost clear Mild Moderate Severe
Group A
Baseline
Week 1
Week 4
Week 8
Week 12
Group B
Baseline
Week 1
Week 4
Week 8
Week 12
Table 20 Pustular psoriasis at non-acral sites (body surface area)
Time Treatment Group Total
N
Unadjusted
Mean
Difference:
(95% CI)
A B
N Mean SD N Mean SD
Baseline
Week 1
Week 4
Week 8
Week 12
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Table 21 Plaque type psoriasis (PASI)
Time Treatment Group Total
N
Unadjusted
Mean
Difference:
(95% CI)
A B
N Mean SD N Mean SD
Baseline
Week 4
Week 8
Week 12
Table 22 Participants global assessment
Time N PGA – N (%)
Clear Nearly clear Mild Moderate Severe Very severe
Group A
Baseline
Week 1
Week 4
Week 8
Week 12
Group B
Baseline
Week 1
Week 4
Week 8
Week 12
Table 23 Palmoplantar quality of life, DLQI and EQ. 5D-3 L
Index
Outcome Time Treatment group Total
N
Unadjusted
mean
difference:
(95% CI)
A B
N Mean SD N Mean SD
Palmoplantar
QoL
Baseline
Week 8
DLQI Baseline
Week 8
EQ 5D-3 L
utility
Baseline
Week 8
Table 24 Summary of safety events type by treatment group
Event
type
Number of Events Number of Participants with
Events
Group A
N =
Group B
N =
Total
N =
Group A
N =
Group B
N =
Total
N =
All events
AE/AR
UAR
SAE/SAR
USAR
Table 25 Serious adverse events and reactions by treatment
group
Id Serious adverse
reaction
Group Onset
date
Resolved
date
Intensity Relatedness
Id Serious adverse
event
Group Onset
date
Resolved
date
Intensity Relatedness
Table 26 Adverse events and reactions by body system class
and treatment group
Body system code Number of events Number of participants
with events
Group
A
N =
Group
B
N =
Total
N =
Group
A
N =
Group
B
N =
Total
N =
Respiratory
Gastro-intestinal
Genito-urinary
Musculo-skeletal
Neurological
Immunological
Dermatological
Allergies
Eyes, ear, nose,
throat
Other
Missing
Table 27 Adverse events at preferred term level by treatment
group
AE term Group A
N events
Group B
N events
Total
N events
Mild events
Moderate events
Severe events
Table 28 Adverse reactions at preferred term level by
treatment group
AE term Group A
N events
Group B
N events
Total
N events
Mild events
Moderate events
Severe events
Cro et al. Trials          (2020) 21:158 Page 14 of 16
Abbreviations
AE: adverse event; APRICOT: Anakinra for Pustular Psoriasis: Response in a
Controlled Trial; AR: adverse reaction; CACE: complier average causal effect;
CI: confidence interval; CONSORT: Consolidated Standards of Reporting Trials;
DLQI: Dermatology Life Quality Index; EME: Efficacy and Mechanism
Evaluation Programme; IDMC: independent data monitoring committee;
IGA: Investigators Global Assessment; ITT: intention-to-treat; MAR: missing at
random; MedDRA: Medical Dictionary for Regulatory Activities; MI: multiple
imputation; MNAR: missing-not-at-random; PASI: Psoriasis Area and Severity
Index; PGA: Participant’s Global Assessment; PPP: palmoplantar pustulosis;
PPPASI: Palmoplantar Pustulosis Area and Severity Index; PPP-
IGA: Palmoplantar Pustulosis Investigators Global Assessment;
REML: restricted maximum likelihood; SAE: serious adverse event;
SAR: serious adverse reaction; SD: standard deviation; SOBI: Swedish Orphan
Biovitrum; SS: safety set; UAR: unexpected adverse reaction;
USAR: unexpected serious adverse reaction
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Table 29 Summary of harm events by relatedness to infection, event type and treatment group
Event Type Total
number of
events
Related to an infection Not related to an infection
Number of events Number of participants Number of events Number of participants
A B A B A B A B A B
Adverse event
Adverse reaction
Unclassified (non-serious)
Serious adverse event
Serious adverse reaction
Total
Table 30 Numbers prescribed medication for harm events
related to an infection by event type and treatment group
Event type Total
number
of events
related to
infection
Prescribed Medication
Number of events Number of participants
A B A B A B
Adverse event
Adverse reaction
Unclassified (non-serious)
Serious adverse event
Serious adverse reaction
Total
Table 31 Details of adverse events which relate to an infection
by treatment group
id Event
term*
Start
date
On-
going
Stop
date
Intensity Related
to IMP
Medication
prescribed
Details of
medication
prescribed
Group
A
Group
B
* Indicates study medication was temporarily interrupted
Table 32 Details of adverse reactions which relate to an
infection by treatment group
id Event
term*
Start
date
On-
going
Stop
date
Intensity Related
to IMP
Medication
prescribed
Details of
medication
prescribed
Group
A
Group
B
* Indicates study medication was temporarily interrupted
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